Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.700
-0.165-1.86%
Volume:51.43M
Turnover:450.06M
Market Cap:100.24B
PE:21.91
High:8.905
Open:8.865
Low:8.685
Close:8.865
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.41
T/O Rate:0.45%
Dividend:0.29
Dividend Rate:3.33%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.28
PE(LYR):21.91
PS:2.74

Loading ...

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy

MT Newswires Live
·
Jul 27

Movement Alert|CSPC PHARMA Declines 3.16% in Regular Trading, Trading at HK$8.3

Market Focus
·
Jul 27

CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval

Simply Wall St.
·
Jul 27

Hong Kong Stock Market Analysis: ChangXin IPO Pressure Weighs, Agricultural Inflation Risks Boost Related Stocks

Stock News
·
Jul 24

CSPC Pharma Gains NMPA Approval for Once-Monthly Paliperidone Palmitate Injection to Treat Schizophrenia

Bulletin Express
·
Jul 24

CSPC Pharma's Paliperidone Palmitate Injection Receives Market Approval

Stock News
·
Jul 24

CSPC Pharma Wins China Approval for Paliperidone Palmitate Schizophrenia Injection

Reuters
·
Jul 24

CSPC Pharmaceutical - Paliperidone Palmitate Injection Receives Marketing Approval

THOMSON REUTERS
·
Jul 24

CSPC Pharmaceutical Group Stock Rises 2.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 24

Movement Alert|CSPC PHARMA Rises 3.23% in Regular Trading, Therapeutic mRNA Vaccine Enters Phase II Clinical Trial

Market Focus
·
Jul 24

CSPC Pharma Starts Phase 2 Trial of HPV Therapeutic Vaccine in China

MT Newswires Live
·
Jul 23

CSPC Pharma Launches Phase II Trial of mRNA Vaccine SYS6026 for HPV16/18-Related Cervical HSIL

Bulletin Express
·
Jul 22

CSPC Pharmaceutical Group Stock Slips 1.1% in Hong Kong

Dow Jones
·
Jul 21

CSPC Pharmaceutical Group Stock Rallies 4.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 20

Movement Alert|CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery

Market Focus
·
Jul 20

CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 17

CSPC Pharmaceutical’s Trastuzumab Envedotin NDA Accepted by China’s NMPA

Bulletin Express
·
Jul 17

CSPC Pharma's New Drug Application for Envituzumab Injection Accepted by Chinese Regulator

Stock News
·
Jul 17

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Trastuzumab Envedotin Injection

THOMSON REUTERS
·
Jul 17

CSPC Pharmaceutical - Product Indicated for Unresectable or Metastatic Her2-positive Breast Cancer in Adults

THOMSON REUTERS
·
Jul 17